Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 23 | 2022 | 744 | 3.180 |
Why?
|
Antigens, Neoplasm | 18 | 2022 | 325 | 2.650 |
Why?
|
CD8-Positive T-Lymphocytes | 23 | 2023 | 558 | 2.640 |
Why?
|
CD4-Positive T-Lymphocytes | 10 | 2019 | 425 | 1.810 |
Why?
|
Membrane Proteins | 11 | 2017 | 1196 | 1.110 |
Why?
|
T-Lymphocytes, Helper-Inducer | 4 | 2015 | 132 | 0.940 |
Why?
|
Epitopes, T-Lymphocyte | 5 | 2013 | 89 | 0.910 |
Why?
|
Antigen Presentation | 4 | 2020 | 209 | 0.900 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2022 | 54 | 0.890 |
Why?
|
Histocompatibility Antigens Class II | 4 | 2013 | 158 | 0.850 |
Why?
|
Receptors, Antigen, T-Cell | 8 | 2023 | 371 | 0.790 |
Why?
|
Leukocytes, Mononuclear | 1 | 2022 | 196 | 0.770 |
Why?
|
Th1 Cells | 7 | 2012 | 164 | 0.760 |
Why?
|
T-Lymphocyte Subsets | 6 | 2020 | 272 | 0.730 |
Why?
|
Genes, T-Cell Receptor | 1 | 2019 | 10 | 0.680 |
Why?
|
Neoplasms | 10 | 2023 | 2898 | 0.650 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 4 | 2021 | 123 | 0.620 |
Why?
|
Cytotoxicity, Immunologic | 5 | 2015 | 213 | 0.580 |
Why?
|
Cell Line, Tumor | 14 | 2022 | 2426 | 0.570 |
Why?
|
T-Lymphocytes | 7 | 2023 | 1195 | 0.540 |
Why?
|
Cancer Vaccines | 5 | 2022 | 156 | 0.540 |
Why?
|
Antigens, CD | 3 | 2015 | 458 | 0.520 |
Why?
|
Immunotherapy | 8 | 2023 | 629 | 0.500 |
Why?
|
Interferon-gamma | 12 | 2015 | 444 | 0.470 |
Why?
|
Mice | 25 | 2023 | 11356 | 0.470 |
Why?
|
T-Lymphocytes, Cytotoxic | 6 | 2017 | 315 | 0.470 |
Why?
|
Cytokines | 7 | 2021 | 778 | 0.460 |
Why?
|
Immunotherapy, Adoptive | 5 | 2022 | 170 | 0.450 |
Why?
|
Tumor Microenvironment | 5 | 2022 | 418 | 0.420 |
Why?
|
Azacitidine | 4 | 2016 | 137 | 0.400 |
Why?
|
Animals | 27 | 2023 | 26589 | 0.360 |
Why?
|
Immunologic Factors | 2 | 2014 | 170 | 0.350 |
Why?
|
Female | 33 | 2022 | 44550 | 0.340 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2010 | 199 | 0.340 |
Why?
|
Immunity | 2 | 2021 | 136 | 0.340 |
Why?
|
Humans | 46 | 2023 | 86678 | 0.340 |
Why?
|
Lymphocyte Activation | 6 | 2022 | 728 | 0.330 |
Why?
|
Th2 Cells | 3 | 2005 | 146 | 0.320 |
Why?
|
Flow Cytometry | 7 | 2020 | 679 | 0.300 |
Why?
|
Cell Survival | 3 | 2020 | 969 | 0.290 |
Why?
|
Tryptophan | 2 | 2022 | 90 | 0.290 |
Why?
|
Dendritic Cells | 3 | 2010 | 425 | 0.290 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2021 | 1197 | 0.280 |
Why?
|
Melanoma | 4 | 2022 | 459 | 0.280 |
Why?
|
Mice, SCID | 5 | 2021 | 252 | 0.270 |
Why?
|
Bone Marrow Cells | 2 | 2006 | 253 | 0.270 |
Why?
|
Leukemia, Myeloid, Acute | 3 | 2017 | 763 | 0.270 |
Why?
|
Immunologic Memory | 2 | 2022 | 152 | 0.260 |
Why?
|
Myeloid-Derived Suppressor Cells | 2 | 2022 | 17 | 0.260 |
Why?
|
Hormones | 1 | 2005 | 141 | 0.250 |
Why?
|
Tumor Necrosis Factor-alpha | 5 | 2015 | 683 | 0.250 |
Why?
|
Receptors, CXCR3 | 2 | 2015 | 12 | 0.240 |
Why?
|
Oleic Acids | 1 | 2023 | 26 | 0.240 |
Why?
|
Retroelements | 1 | 2023 | 44 | 0.230 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2003 | 32 | 0.230 |
Why?
|
Vitamin D | 1 | 2006 | 261 | 0.230 |
Why?
|
Cells, Cultured | 8 | 2018 | 2819 | 0.230 |
Why?
|
Autoimmune Diseases | 1 | 2005 | 241 | 0.230 |
Why?
|
Antibodies, Monoclonal | 3 | 2010 | 1376 | 0.220 |
Why?
|
T Cell Transcription Factor 1 | 1 | 2022 | 23 | 0.210 |
Why?
|
NAD | 1 | 2022 | 65 | 0.210 |
Why?
|
Mammary Neoplasms, Animal | 1 | 2022 | 54 | 0.210 |
Why?
|
Receptors, CXCR6 | 1 | 2021 | 5 | 0.210 |
Why?
|
Monitoring, Immunologic | 1 | 2021 | 17 | 0.210 |
Why?
|
Programmed Cell Death 1 Receptor | 2 | 2015 | 159 | 0.200 |
Why?
|
Neutrophils | 2 | 2019 | 307 | 0.200 |
Why?
|
Claudins | 1 | 2022 | 33 | 0.200 |
Why?
|
Repressor Proteins | 2 | 2021 | 403 | 0.200 |
Why?
|
Graft vs Host Disease | 2 | 2023 | 365 | 0.200 |
Why?
|
Quinoxalines | 1 | 2021 | 50 | 0.190 |
Why?
|
Carbazoles | 1 | 2021 | 51 | 0.190 |
Why?
|
Carboplatin | 1 | 2021 | 286 | 0.190 |
Why?
|
Immunomodulation | 1 | 2020 | 55 | 0.190 |
Why?
|
Cell Differentiation | 2 | 2006 | 1458 | 0.190 |
Why?
|
Genetic Therapy | 2 | 2018 | 342 | 0.180 |
Why?
|
Leukemia L1210 | 1 | 2000 | 12 | 0.180 |
Why?
|
Triple Negative Breast Neoplasms | 1 | 2022 | 137 | 0.180 |
Why?
|
Food Deprivation | 1 | 2000 | 24 | 0.180 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2021 | 154 | 0.180 |
Why?
|
Exosomes | 1 | 2020 | 50 | 0.180 |
Why?
|
Interleukin-10 | 1 | 2020 | 149 | 0.180 |
Why?
|
Paclitaxel | 1 | 2021 | 460 | 0.180 |
Why?
|
Jurkat Cells | 2 | 2018 | 77 | 0.180 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2020 | 138 | 0.170 |
Why?
|
DNA Methylation | 4 | 2021 | 628 | 0.170 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 318 | 0.170 |
Why?
|
Peptide Fragments | 2 | 2013 | 460 | 0.170 |
Why?
|
Neoplasm Proteins | 3 | 2014 | 532 | 0.170 |
Why?
|
Cell Engineering | 1 | 2018 | 5 | 0.160 |
Why?
|
Chromatin | 1 | 2021 | 381 | 0.160 |
Why?
|
Interleukin-17 | 2 | 2009 | 101 | 0.160 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2012 | 295 | 0.160 |
Why?
|
Gene Library | 1 | 2018 | 130 | 0.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 2438 | 0.160 |
Why?
|
Mice, Inbred BALB C | 6 | 2021 | 1047 | 0.150 |
Why?
|
Skin Neoplasms | 1 | 2022 | 546 | 0.150 |
Why?
|
Carcinoma | 2 | 2012 | 436 | 0.150 |
Why?
|
Neoplasms, Glandular and Epithelial | 2 | 2015 | 74 | 0.150 |
Why?
|
Cytoreduction Surgical Procedures | 1 | 2017 | 73 | 0.150 |
Why?
|
Cell Proliferation | 3 | 2021 | 1579 | 0.150 |
Why?
|
Interleukin-2 | 2 | 2009 | 249 | 0.150 |
Why?
|
HLA-B44 Antigen | 1 | 2016 | 3 | 0.140 |
Why?
|
HLA-B27 Antigen | 1 | 2016 | 8 | 0.140 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2008 | 203 | 0.140 |
Why?
|
Colonic Neoplasms | 1 | 2021 | 558 | 0.140 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2017 | 236 | 0.140 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 376 | 0.140 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2023 | 878 | 0.140 |
Why?
|
Coculture Techniques | 1 | 2015 | 164 | 0.130 |
Why?
|
Genetic Vectors | 2 | 2018 | 439 | 0.130 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 1384 | 0.130 |
Why?
|
Mice, Inbred C57BL | 6 | 2015 | 3095 | 0.130 |
Why?
|
Mice, Transgenic | 6 | 2021 | 1540 | 0.130 |
Why?
|
Nephrectomy | 1 | 2017 | 294 | 0.130 |
Why?
|
Epigenesis, Genetic | 2 | 2021 | 481 | 0.120 |
Why?
|
Tumor Burden | 1 | 2015 | 289 | 0.120 |
Why?
|
Transplantation, Heterologous | 1 | 2015 | 363 | 0.120 |
Why?
|
Signal Transduction | 3 | 2015 | 3243 | 0.120 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2013 | 8 | 0.120 |
Why?
|
Myelodysplastic Syndromes | 1 | 2017 | 346 | 0.120 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 1075 | 0.120 |
Why?
|
Radiosurgery | 1 | 2017 | 272 | 0.120 |
Why?
|
Aged | 10 | 2022 | 18423 | 0.120 |
Why?
|
Cell Line, Transformed | 1 | 2013 | 154 | 0.120 |
Why?
|
Methyltransferases | 1 | 2015 | 182 | 0.120 |
Why?
|
Cytotoxicity Tests, Immunologic | 3 | 2010 | 44 | 0.110 |
Why?
|
Carcinoma, Renal Cell | 1 | 2017 | 426 | 0.110 |
Why?
|
Vaccinia virus | 1 | 2012 | 19 | 0.110 |
Why?
|
Vaccines, Synthetic | 1 | 2012 | 55 | 0.100 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2012 | 46 | 0.100 |
Why?
|
Enzyme Inhibitors | 1 | 2015 | 639 | 0.100 |
Why?
|
Peptides | 2 | 2012 | 639 | 0.100 |
Why?
|
Lymphoma | 2 | 2003 | 262 | 0.100 |
Why?
|
Trans-Activators | 2 | 2004 | 429 | 0.100 |
Why?
|
Antibody Formation | 2 | 2012 | 171 | 0.100 |
Why?
|
Mannose-Binding Lectins | 1 | 2010 | 6 | 0.100 |
Why?
|
Mutation | 2 | 2020 | 3968 | 0.100 |
Why?
|
Autoantigens | 1 | 2011 | 127 | 0.090 |
Why?
|
Killer Cells, Natural | 2 | 2004 | 267 | 0.090 |
Why?
|
Lectins, C-Type | 1 | 2010 | 85 | 0.090 |
Why?
|
Lung Neoplasms | 1 | 2023 | 2262 | 0.090 |
Why?
|
Mice, Knockout | 4 | 2021 | 1924 | 0.090 |
Why?
|
Vaccination | 1 | 2012 | 254 | 0.090 |
Why?
|
Neoplasm Transplantation | 3 | 2021 | 391 | 0.090 |
Why?
|
Long Interspersed Nucleotide Elements | 2 | 2023 | 12 | 0.090 |
Why?
|
RNA, Messenger | 3 | 2022 | 1981 | 0.090 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 1721 | 0.090 |
Why?
|
Interleukin-4 | 3 | 2004 | 127 | 0.090 |
Why?
|
Receptors, Cell Surface | 1 | 2010 | 286 | 0.090 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2006 | 112 | 0.080 |
Why?
|
Immune Tolerance | 1 | 2011 | 337 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2014 | 879 | 0.080 |
Why?
|
Middle Aged | 8 | 2021 | 25040 | 0.080 |
Why?
|
Autoantibodies | 2 | 2023 | 267 | 0.080 |
Why?
|
Chemokines, CC | 2 | 2004 | 34 | 0.080 |
Why?
|
Cloning, Molecular | 3 | 2018 | 646 | 0.070 |
Why?
|
Immunoglobulin G | 2 | 2023 | 456 | 0.070 |
Why?
|
Lymphocyte Depletion | 2 | 2004 | 97 | 0.070 |
Why?
|
Cell- and Tissue-Based Therapy | 2 | 2003 | 49 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2021 | 458 | 0.070 |
Why?
|
Phosphorylation | 2 | 2006 | 1106 | 0.070 |
Why?
|
STAT1 Transcription Factor | 1 | 2006 | 52 | 0.070 |
Why?
|
Cholecalciferol | 1 | 2006 | 35 | 0.070 |
Why?
|
Retroviridae | 3 | 2018 | 79 | 0.070 |
Why?
|
Immunity, Cellular | 1 | 2006 | 177 | 0.070 |
Why?
|
HLA-A Antigens | 1 | 2005 | 44 | 0.070 |
Why?
|
Interferon-beta | 1 | 2006 | 125 | 0.070 |
Why?
|
Galactosylceramides | 1 | 2004 | 8 | 0.060 |
Why?
|
Ovalbumin | 3 | 2015 | 109 | 0.060 |
Why?
|
Graft vs Host Reaction | 1 | 2004 | 15 | 0.060 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 2360 | 0.060 |
Why?
|
Bronchial Hyperreactivity | 1 | 2004 | 77 | 0.060 |
Why?
|
Prognosis | 2 | 2023 | 3680 | 0.060 |
Why?
|
Dairy Products | 1 | 2023 | 11 | 0.060 |
Why?
|
Red Meat | 1 | 2023 | 10 | 0.060 |
Why?
|
Eosinophilia | 1 | 2004 | 84 | 0.060 |
Why?
|
Apoptosis | 2 | 2021 | 1683 | 0.060 |
Why?
|
Fatty Acids, Volatile | 1 | 2023 | 32 | 0.060 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2023 | 66 | 0.060 |
Why?
|
Milk | 1 | 2023 | 53 | 0.060 |
Why?
|
Sheep | 1 | 2023 | 239 | 0.060 |
Why?
|
Immunity, Humoral | 2 | 2014 | 67 | 0.060 |
Why?
|
Endosomes | 2 | 2015 | 75 | 0.060 |
Why?
|
Antigens, Ly | 1 | 2003 | 37 | 0.060 |
Why?
|
CX3C Chemokine Receptor 1 | 1 | 2023 | 5 | 0.060 |
Why?
|
Mastocytoma | 1 | 2003 | 4 | 0.060 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2023 | 107 | 0.060 |
Why?
|
CD3 Complex | 1 | 2003 | 135 | 0.060 |
Why?
|
Cattle | 1 | 2023 | 376 | 0.060 |
Why?
|
Galectin 3 | 1 | 2023 | 17 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 1992 | 0.060 |
Why?
|
Immunization | 1 | 2003 | 158 | 0.060 |
Why?
|
Hypersensitivity | 1 | 2004 | 154 | 0.060 |
Why?
|
Cyclic AMP | 1 | 2023 | 273 | 0.060 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2003 | 100 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2021 | 1041 | 0.050 |
Why?
|
Transduction, Genetic | 2 | 2018 | 153 | 0.050 |
Why?
|
gp100 Melanoma Antigen | 1 | 2022 | 12 | 0.050 |
Why?
|
Granzymes | 1 | 2022 | 93 | 0.050 |
Why?
|
Male | 6 | 2022 | 40988 | 0.050 |
Why?
|
Immunohistochemistry | 2 | 2017 | 1753 | 0.050 |
Why?
|
B7-H1 Antigen | 1 | 2023 | 250 | 0.050 |
Why?
|
Aged, 80 and over | 3 | 2017 | 6513 | 0.050 |
Why?
|
Chemokines | 1 | 2021 | 73 | 0.050 |
Why?
|
Transplantation, Homologous | 1 | 2023 | 996 | 0.050 |
Why?
|
Radiation | 1 | 2020 | 15 | 0.050 |
Why?
|
Carrier Proteins | 1 | 2004 | 673 | 0.050 |
Why?
|
Methylation | 1 | 2021 | 251 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2005 | 977 | 0.050 |
Why?
|
Antibodies | 2 | 2015 | 350 | 0.050 |
Why?
|
Phenotype | 2 | 2017 | 2380 | 0.040 |
Why?
|
Sequence Analysis, RNA | 1 | 2021 | 217 | 0.040 |
Why?
|
Granulocytes | 1 | 2019 | 37 | 0.040 |
Why?
|
Amino Acid Substitution | 1 | 2020 | 339 | 0.040 |
Why?
|
Muromonab-CD3 | 1 | 2019 | 69 | 0.040 |
Why?
|
Complement C3 | 1 | 2019 | 58 | 0.040 |
Why?
|
CD28 Antigens | 1 | 2019 | 88 | 0.040 |
Why?
|
Histones | 1 | 2021 | 311 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2017 | 1961 | 0.040 |
Why?
|
Frozen Sections | 1 | 2018 | 48 | 0.040 |
Why?
|
Interferon Inducers | 1 | 2017 | 3 | 0.040 |
Why?
|
Carboxymethylcellulose Sodium | 1 | 2017 | 7 | 0.040 |
Why?
|
Poly I-C | 1 | 2017 | 16 | 0.040 |
Why?
|
Treatment Outcome | 3 | 2017 | 7998 | 0.040 |
Why?
|
Polylysine | 1 | 2017 | 33 | 0.040 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 187 | 0.040 |
Why?
|
Analysis of Variance | 1 | 2000 | 912 | 0.040 |
Why?
|
Ligands | 2 | 2012 | 433 | 0.040 |
Why?
|
Up-Regulation | 1 | 2020 | 715 | 0.040 |
Why?
|
Myeloid Cells | 1 | 2017 | 98 | 0.040 |
Why?
|
Amino Acid Sequence | 2 | 2011 | 2062 | 0.040 |
Why?
|
Survival Analysis | 1 | 2021 | 1538 | 0.040 |
Why?
|
Alleles | 1 | 2020 | 1128 | 0.040 |
Why?
|
Adult | 4 | 2017 | 25659 | 0.040 |
Why?
|
Asthma | 1 | 2004 | 955 | 0.040 |
Why?
|
Molecular Sequence Data | 2 | 2011 | 3030 | 0.030 |
Why?
|
Neoplasm Staging | 1 | 2021 | 1939 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 1 | 2020 | 589 | 0.030 |
Why?
|
Microtubule-Organizing Center | 1 | 2015 | 5 | 0.030 |
Why?
|
Antibodies, Neoplasm | 1 | 2016 | 84 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 916 | 0.030 |
Why?
|
Receptors, CCR5 | 1 | 2015 | 17 | 0.030 |
Why?
|
Neoplasm Grading | 1 | 2017 | 357 | 0.030 |
Why?
|
Transcriptome | 1 | 2020 | 580 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2015 | 134 | 0.030 |
Why?
|
Receptors, CCR2 | 1 | 2015 | 35 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2017 | 751 | 0.030 |
Why?
|
Cell Line | 2 | 2010 | 2469 | 0.030 |
Why?
|
Microtubules | 1 | 2015 | 119 | 0.030 |
Why?
|
Lysosomes | 1 | 2015 | 104 | 0.030 |
Why?
|
Adoptive Transfer | 1 | 2015 | 168 | 0.030 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 266 | 0.030 |
Why?
|
Cytoplasm | 1 | 2015 | 281 | 0.030 |
Why?
|
Melanoma, Experimental | 1 | 2015 | 103 | 0.030 |
Why?
|
Heterografts | 1 | 2015 | 98 | 0.030 |
Why?
|
Chemokine CCL11 | 2 | 2004 | 11 | 0.030 |
Why?
|
Pilot Projects | 1 | 2017 | 840 | 0.030 |
Why?
|
STAT6 Transcription Factor | 2 | 2004 | 28 | 0.030 |
Why?
|
Immunotherapy, Active | 1 | 2014 | 15 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2015 | 526 | 0.030 |
Why?
|
Haplotypes | 1 | 2016 | 642 | 0.030 |
Why?
|
Laboratory Proficiency Testing | 1 | 2013 | 5 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 1686 | 0.030 |
Why?
|
Protein Structure, Tertiary | 1 | 2015 | 736 | 0.030 |
Why?
|
Laboratories | 1 | 2013 | 43 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 1056 | 0.030 |
Why?
|
Doxorubicin | 1 | 2014 | 295 | 0.030 |
Why?
|
Staining and Labeling | 1 | 2013 | 165 | 0.030 |
Why?
|
International Cooperation | 1 | 2013 | 127 | 0.030 |
Why?
|
Spleen | 2 | 2004 | 430 | 0.030 |
Why?
|
Fowlpox virus | 1 | 2012 | 1 | 0.030 |
Why?
|
Ikaros Transcription Factor | 1 | 2012 | 25 | 0.030 |
Why?
|
Biomarkers, Tumor | 1 | 2020 | 1464 | 0.030 |
Why?
|
Gene Expression Regulation | 2 | 2015 | 1921 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 861 | 0.030 |
Why?
|
Cytosol | 1 | 2012 | 189 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2012 | 100 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 1169 | 0.030 |
Why?
|
Leukocyte Common Antigens | 1 | 2011 | 46 | 0.030 |
Why?
|
Cell Movement | 1 | 2015 | 758 | 0.030 |
Why?
|
Polyethylene Glycols | 1 | 2014 | 364 | 0.030 |
Why?
|
T-Box Domain Proteins | 1 | 2012 | 118 | 0.020 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2010 | 39 | 0.020 |
Why?
|
Cross-Priming | 1 | 2010 | 48 | 0.020 |
Why?
|
Clone Cells | 1 | 2010 | 213 | 0.020 |
Why?
|
Antigen-Presenting Cells | 1 | 2010 | 139 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2012 | 547 | 0.020 |
Why?
|
Disease Progression | 1 | 2014 | 1532 | 0.020 |
Why?
|
Gene Expression | 1 | 2014 | 1284 | 0.020 |
Why?
|
Stereoisomerism | 1 | 2009 | 102 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2011 | 381 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2010 | 557 | 0.020 |
Why?
|
Interleukin-1beta | 1 | 2008 | 78 | 0.020 |
Why?
|
Forkhead Transcription Factors | 1 | 2009 | 166 | 0.020 |
Why?
|
Freund's Adjuvant | 1 | 2007 | 26 | 0.020 |
Why?
|
Cell Division | 1 | 2009 | 696 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2014 | 1313 | 0.020 |
Why?
|
Transfection | 1 | 2009 | 896 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2008 | 256 | 0.020 |
Why?
|
Lymphocytes | 1 | 2009 | 464 | 0.020 |
Why?
|
Protein Binding | 1 | 2010 | 1457 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2013 | 2706 | 0.020 |
Why?
|
Interleukin-3 | 1 | 2006 | 36 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2009 | 533 | 0.020 |
Why?
|
WT1 Proteins | 1 | 2005 | 19 | 0.020 |
Why?
|
HLA-A24 Antigen | 1 | 2005 | 20 | 0.020 |
Why?
|
Lentivirus | 1 | 2005 | 36 | 0.020 |
Why?
|
Young Adult | 1 | 2017 | 5980 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2006 | 188 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2009 | 669 | 0.020 |
Why?
|
Mucus | 1 | 2004 | 19 | 0.020 |
Why?
|
Genetic Engineering | 1 | 2005 | 114 | 0.020 |
Why?
|
Administration, Intranasal | 1 | 2004 | 136 | 0.020 |
Why?
|
Adolescent | 1 | 2017 | 8984 | 0.020 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2004 | 121 | 0.020 |
Why?
|
Suppressor of Cytokine Signaling 1 Protein | 1 | 2004 | 7 | 0.020 |
Why?
|
Suppressor of Cytokine Signaling Proteins | 1 | 2004 | 20 | 0.020 |
Why?
|
Culture Media | 1 | 2004 | 147 | 0.010 |
Why?
|
Blotting, Northern | 1 | 2004 | 256 | 0.010 |
Why?
|
Mice, Inbred Strains | 1 | 2004 | 307 | 0.010 |
Why?
|
Tyrosine | 1 | 2004 | 133 | 0.010 |
Why?
|
In Vitro Techniques | 1 | 2005 | 989 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2004 | 393 | 0.010 |
Why?
|
Kidney | 1 | 2009 | 1242 | 0.010 |
Why?
|
Lymphoma, B-Cell | 1 | 2004 | 103 | 0.010 |
Why?
|
Leukemia | 1 | 2005 | 320 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2004 | 1015 | 0.010 |
Why?
|
Down-Regulation | 1 | 2004 | 506 | 0.010 |
Why?
|
Blotting, Western | 1 | 2004 | 782 | 0.010 |
Why?
|
Tissue Donors | 1 | 2004 | 464 | 0.010 |
Why?
|
Fibroblasts | 1 | 2004 | 729 | 0.010 |
Why?
|
Survival Rate | 1 | 2003 | 1864 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 2004 | 724 | 0.010 |
Why?
|
Lung | 1 | 2004 | 1169 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2004 | 2231 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2003 | 1208 | 0.010 |
Why?
|
Time Factors | 1 | 2004 | 5214 | 0.010 |
Why?
|